MAPS$0.350
$0.370
Chart
Performance
Key Stats
AI MAPS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralWM Technology (MAPS) operates in a growing market with potential, but faces challenges in profitability and consistent growth. Technical indicators suggest a neutral short-term outlook. Investors should monitor revenue trends and operational efficiency.
Thematic
WM Technology is positioned within the expanding cannabis market, benefiting from increasing legalization and adoption of technology solutions for the sector. However, market growth and regulatory shifts are key external factors.
Fundamental
WM Technology shows revenue growth and is transitioning towards profitability. However, past losses and current P/E ratios indicate a company still in a development/turnaround phase. Strong cash position is a positive.
Technical
The stock is trading around its key moving averages, indicating a lack of strong directional momentum. Oscillators are mixed, suggesting consolidation. Support levels are being tested.
| Factor | Score |
|---|---|
| Cannabis Market Growth | 85 |
| Technology Adoption in Cannabis | 80 |
| Regulatory Environment | 55 |
| Competition | 60 |
| User Engagement (Weedmaps) | 75 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 65 |
| Growth | 40 |
| Balance Sheet Health | 80 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Support & Resistance | 60 |
| Volume | 60 |
| Chart Patterns | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Attractive Valuation Metrics
The company exhibits a P/E ratio of 22.4 (TTM) and a P/S ratio of 1.2 (TTM), suggesting potential undervaluation relative to its trailing earnings and sales. The forward P/E for 2024 is 19.0, indicating positive expectations for future profitability.
Positive Net Income and Revenue Growth
The company has achieved positive net income in the trailing twelve months ($7.33 million) and shows revenue growth, with $184.51 million in 2024. Net margin has improved to 4.1% in 2024 from -5.3% in 2023.
Bearish Points (8)
Significant Short-Term Underperformance
The stock has experienced a notable decline over the past 6 months (-26.99%) and year-to-date (-33.03%), indicating recent negative investor sentiment and price depreciation.
Inconsistent Profitability
The company has a history of volatile net income, including significant losses in 2022 (-$115.99 million) and 2023 (-$9.90 million), despite positive net income in 2024 ($7.64 million). This suggests a lack of stable profitability.
Calendar
August 2025
8
Next Earnings Date
H: $
A: $
L: $
H: 45.00M
A: 45.00M
L: 45.00M
Profile
WM Technology, Inc., an online cannabis marketplace, provides ecommerce and compliance software solutions to retailers and brands in cannabis market in the United States and internationally. The company offers Weedmaps marketplace that allows cannabis users to search for and browse cannabis products from retailers and brands, and reserve products from local retailers; and education and learning information to help newer consumers learn about the types of products to purchase. It also provides monthly subscription-based business software solutions, including WM Listings, WM Orders, WM Store, WM Connectors, and WM Insights as well as other add-on products, such as WM Ads and WM Dispatch. WM Technology, Inc. was founded in 2008 and is headquartered in Irvine, California.
Seasonals
Price Target
2.61 USD
The 39 analysts offering 1 year price forecasts for MAPS have a max estimate of 2.61 and a min estimate of 2.61.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Through its Janssen pharmaceutical division, JNJ developed and commercialized Spravato (esketamine), an FDA-approved dissociative antidepressant, representing a significant breakthrough in novel mental health treatments that aligns conceptually with the broader psychedelic-assisted therapy movement.
Weight: 95
A global leader in developing psilocybin therapy (COMP360) for treatment-resistant depression (TRD), with ongoing Phase 3 clinical trials, directly aligning with MAPS' mission of bringing novel psychedelic therapies to market.
Weight: 90
A leading psychedelic biotech company with a diverse portfolio of drug candidates addressing various mental health conditions, including psilocybin, DMT, and MDMA analogues, and a strategy to invest in and develop multiple psychedelic compounds.
Weight: 88
Focused on developing psychedelic-inspired therapies for addiction and mental health disorders, with significant clinical programs for LSD and other novel compounds, aiming to deliver FDA-approved treatments.